Post-treatment with PT302, a long-acting Exendin-4 sustained release formulation, reduces dopaminergic neurodegeneration in a 6-Hydroxydopamine rat model of Parkinson's disease

Scientific Reports
Shuchun ChenYun Wang

Abstract

We previously demonstrated that pretreatment with Exendin-4, a glucagon-like peptide-1 (GLP-1) receptor agonist, reduces 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) -mediated dopaminergic neurodegeneration. The use of GLP-1 or Exendin-4 for Parkinson's disease (PD) patients is limited by their short half-lives. The purpose of this study was to evaluate a new extended release Exendin-4 formulation, PT302, in a rat model of PD. Subcutaneous administration of PT302 resulted in sustained elevations of Exendin-4 in plasma for >20 days in adult rats. To define an efficacious dose within this range, rats were administered PT302 once every 2 weeks either before or following the unilaterally 6-hydroxydopamine lesioning. Pre- and post-treatment with PT302 significantly reduced methamphetamine-induced rotation after lesioning. For animals given PT302 post lesion, blood and brain samples were collected on day 47 for measurements of plasma Exendin-4 levels and brain tyrosine hydroxylase immunoreactivity (TH-IR). PT302 significantly increased TH-IR in the lesioned substantia nigra and striatum. There was a significant correlation between plasma Exendin-4 levels and TH-IR in the substantia nigra and striatum on the lesioned side. Our ...Continue Reading

References

Apr 5, 2002·Journal of Molecular Neuroscience : MN·Abba J KastinWeihong Pan
Mar 12, 2003·International Journal of Obesity and Related Metabolic Disorders : Journal of the International Association for the Study of Obesity·A J Kastin, V Akerstrom
Sep 16, 2003·Neuron·William Dauer, Serge Przedborski
Jan 19, 2005·Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Métabolisme·Y Yamada, Y Seino
Jan 26, 2007·Diabetes Care·Gang HuJaakko Tuomilehto
Jul 5, 2008·Diabetes Care·Jane A DriverGiancarlo Logroscino
Jan 24, 2009·Proceedings of the National Academy of Sciences of the United States of America·Yazhou LiNigel H Greig
Aug 13, 2010·American Journal of Physiology. Regulatory, Integrative and Comparative Physiology·Jill K MorrisPaige C Geiger
Mar 8, 2011·Diabetes Care·Qun XuHonglei Chen
May 7, 2011·Cellular and Molecular Neurobiology·Lloyd A GreeneCristina Malagelada
Jun 28, 2011·Experimental Neurology·J K MorrisJ A Stanford
Dec 23, 2011·Parkinsonism & Related Disorders·Vernice Jackson-LewisSerge Przedborski
Feb 22, 2012·Brain : a Journal of Neurology·Iciar Aviles-OlmosThomas Foltynie
Feb 26, 2013·Movement Disorders : Official Journal of the Movement Disorder Society·Stacey L KowalAnjali Jain
May 21, 2013·Cell Metabolism·Jonathan E Campbell, Daniel J Drucker
Jun 4, 2013·The Journal of Clinical Investigation·Iciar Aviles-OlmosThomas Foltynie
Jan 1, 2014·The European Journal of Neuroscience·Simon R W Stott, Roger A Barker
Feb 4, 2014·Neuropharmacology·Alessandro Ciccarelli, Maurizio Giustetto
Feb 18, 2014·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Thomas Foltynie, Iciar Aviles-Olmos
Mar 4, 2014·Progress in Neurobiology·Fares BassilWassilios G Meissner
Mar 26, 2014·Journal of Parkinson's Disease·Iciar Aviles-OlmosThomas Foltynie
Jul 26, 2015·Progress in Neurobiology·Matthieu F BastideErwan Bézard
Apr 12, 2016·Frontiers in Aging Neuroscience·Juhyun Song, Jongpil Kim
Jul 19, 2016·Scientific Reports·Giuseppe PerruoloPietro Formisano
Oct 22, 2016·Journal of Parkinson's Disease·Zuzanna KurowskaSatish Medicetty
Dec 22, 2016·International Journal of Molecular Medicine·Noriko NakanoYasuko Kitagishi
Jan 14, 2017·Expert Opinion on Pharmacotherapy·Filip K KnopTina Vilsbøll
Feb 6, 2017·Journal of Neural Transmission·Ole-Bjørn Tysnes, Anette Storstein

❮ Previous
Next ❯

Citations

Nov 13, 2018·Basic & Clinical Pharmacology & Toxicology·Michelle Khai Khun Yap, Nurhamimah Misuan
Apr 3, 2019·Brain Injury : [BI]·Damla ErbilHale Yapıcı Eser
Apr 5, 2020·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Yu-Wen HungSheau-Ling Lee
May 16, 2020·Expert Opinion on Investigational Drugs·Elliot J GlotfeltyNigel H Greig
Aug 8, 2020·Expert Review of Neurotherapeutics·Daniele ColomboCharlotte Keywood
Sep 21, 2019·Drug Discovery Today·Henrique de Oliveira AmaralMárcia R Mortari
Apr 6, 2021·Frontiers in Neuroscience·Simon R W StottPatrik Brundin
Apr 17, 2021·ACS Pharmacology & Translational Science·Vicki WangYuan-Hao Chen
May 7, 2021·Critical Reviews in Food Science and Nutrition·Yiwen ChengZongxin Ling
Aug 10, 2019·ACS Pharmacology & Translational Science·Elliot J GlotfeltyNigel H Greig
Oct 3, 2019·Journal of Medicinal Chemistry·Rie SuzukiMiles Congreve
Jan 13, 2022·Neural Regeneration Research·Carmen M LabandeiraAna I Rodriguez-Perez

❮ Previous
Next ❯

Methods Mentioned

BETA
ELISA

Clinical Trials Mentioned

NCT02953665

Software Mentioned

ImageJ

Related Concepts

Related Feeds

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.

Allen Institute for Brain Science Network

The Allen Institute for Brain Science Network is a not-for-profit biomedical research organization that provides open access to multiple neuroscience tools and resources. Find the latest research from tjr Allen Institute for Brain Science Network here.